Nycomed Imaging As

Pharmacia Ab

Goran Pettersson

Klaes Golman

Jo Klaveness

Arne Berg

Peter Leander

Pangl Rongved

Ib Leunbach

Pal Rongved

Anders K Bjork

Anne Kjersti Fahlvik

Gunnar Andersson

Curt Nordvi

Lisbeth Abramo

Wolfgang H Gunther

Elisabeth Seifert

Arne Nilsson

Torbjorn Lundstedt

Anne Jacobsen

Liv-Ingrid Degangrdstuen

Catarina Ludwig

Jin Chang Wu

The invention provides a method of functional imaging of a human or non-human animal body, which method comprises administering into the gastrointestinal tract of a said body an effective amount of a composition comprising (a) a first contrast agent comprising a physiologically tolerable manganese compound or a salt thereof, together with (b) a second contrast agent, and generating a functional image of the gastrointestinal tract of said body. This imaging technique has surprisingly been found to provide clear delineation of those portions of the gut wall in which manganese uptake is occurring, thereby enabling not only the detection of tumors in the gut, but also the identification of regions of the gut which may be functioning abnormally.

Determination of non-functioning areas of the g.i. tract using MRI of

There is provided a contrast medium composition comprising: (a) a first contrast agent comprising a physiologically tolerable manganese compound, a physiologically tolerable reducing compound containing an .alpha.-hydroxy ketone group, or salt thereof, having a manganese concentration of at least 0.3 mM or being in a dosage unit form containing at least 300 .mu.mol manganese, together with (b) a second contrast agent. Such compositions have been found to be particularly suited to imaging of the liver.

Contrast agents for MRI using a manganese compound and kojic acid

There is provided a contrast medium composition comprising: (a) a first contrast agent comprising a physiologically tolerable manganese compound together with an uptake promoter, having a manganese concentration of at least 0.3 mM or being in a dosage unit form containing at least 300 .mu.mol manganese, wherein the uptake promoter comprises a physiologically tolerable reducing compound containing an .alpha.-hydroxy ketone group or a physiologically tolerable acid containing .alpha.- and/or .beta.- hydroxy or amino groups, or a salt thereof, and/or vitamin D; together with (b) a second contrast agent. Such compositions are particularly suitable for imaging of the liver.

Composition and method of MRI using both a positive and a negative

There is provided a contrast medium composition for magnetic resonance imaging comprising a physiologically tolerable manganese compound, a physiologically tolerable reducing compound containing an .alpha.-hydroxy ketone group, or salt thereof and a physiologically tolerable carrier or excipient, having a manganese concentration of at least 0.3 mM or being in a dosage unit form containing at least 300 .mu.mol manganese. Such compositions are particularly suitable for imaging of the liver.

Contrast medium for magnetic resonance imaging using physiologically

Nicotinic acid esters

Growing community of inventors

Hjarup, Sweden

Goran Pettersson